Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Submission of Report to BLA - Cervarix, August 2, 2007

Record of Telephone Conversation
STN Number: 125259/0
Manufacturer: GlaxoSmithKline Biologicals
Product: Human Papillomavirus Vaccine, ASO4 Adjuvant-Adsorbed
To: File
From: Helen S. Gemignani, Regulatory Project Manager
Subject: Submission of Report to BLA
Telecon Date: 02-Aug-2007 Telecon Time: 08:33am
Telecon Initiated by: Helen S. Gemignani
Contact Phone: 610 787-3726


 Summary of Telecon

I advised Mr. Whitman to send a copy of the Preliminary Safety Assessment of Adverse Events report to the BLA.

End of Teleconference

FDA Participants

  • Helen S. Gemignani

GSK Participants

  • Matt Whitman

Page Last Updated: 04/14/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English